VIAtab™ is an oral formulation of insulin designed to be administered sublingually. This therapy is a tablet that dissolves in minutes when placed under the tongue. In a Phase I study, VIAtab™ delivered insulin to the blood stream quickly and resembled the first-phase insulin release spike found in healthy individuals. An oral insulin therapy would be more convenient than currently available injectable or inhalable therapies. We expect this convenience to result in increased insulin usage by the currently underserved early-stage patients with Type 2 diabetes and create better long-term outcomes for this patient population.
Osteoporosis Product Candidates
Biodel has two osteoporosis therapies in the pre-clinical development stage.
Both peptide hormone therapies utilize our VIAdel™ technology to deliver peptide hormones to the body. These peptide hormone therapies regulate calcium and phosphorus metabolism and are released in quick bursts to control bone cell activity. VIAmass™ and VIAcal™ may more closely match the natural spike of hormone levels necessary to produce the desired outcome of new bone formation and/or less bone resorption. Current treatments rely on quick delivery of these hormones to produce clinical benefit.